AMAlessandro Magliozzi

Alessandro Magliozzi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alessandro Magliozzi has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Alfonso Fasano

    Department of Biomedical Sciences Humanitas University Milan Italy

    2 shared publications
  • Alessandra Nicoletti

    Department “G.F. Ingrassia”, Section of Neurosciences, University of Catania, Catania, Italy

    1 shared publication
  • Andrea Pilotto

    Department of Clinical and Experimental Sciences, Neurology Unit University of Brescia Brescia Italy

    1 shared publication
  • Angela Sandri

    Neurology Unit, Movement Disorders Division, Department of Neurosciences, Biomedicine and Movement Sciences University of Verona Verona Italy

    1 shared publication
  • Anthony E. Lang

    Edmond J. Safra Program in Parkinson's Disease, Morton and Gloria Shulman Movement Disorders Clinic Toronto Western Hospital, University Health Network Toronto Ontario Canada

    1 shared publication
  • Benedetta Demartini

    Aldo Ravelli Research Center for Neurotechnology and Experimental Brain Therapeutics University of Milan Milan Italy

    1 shared publication

Latest Publications

  • Open Access

    Pain in Functional Motor Disorders: Clinical Correlates From the Italian Registry

    by Veronica Nisticò, Benedetta Demartini, Christian Geroin, Enrico Marcuzzo, Angela Sandri, Luigi Michele Romito, Roberto Eleopra, Lucia Tesolin, Francesco de Bertoldi, Alessandra Nicoletti, et al.

    Background: Pain is a frequent and disabling symptom in patients with Functional Motor Disorders (FMD), yet its clinical correlates and impact have not been characterized in large, representative cohorts. The aims of this study were to identify clinical predictors and correlates of pain intensity and interference among FMD patients. Methods: We conducted a cross‐sectional analysis within the Italian Registry of Functional Motor Disorders, including 466 adults with FMD recruited from 25 movement disorders centers. Pain was assessed using the Brief Pain Inventory (BPI), which captures pain experienced during the 24 h prior to assessment, alongside sociodemographic, clinical, and psychometric data on depression, anxiety, alexithymia, fatigue, and quality of life. Results: Pain was reported by 78.8% of participants. Fibromyalgia strongly predicted pain, whereas comorbid epilepsy was linked to reduced risk. The presence of pain was associated with a poorer self‐reported sense of physical health. Among patients with pain, higher intensity and interference were associated with younger age, Restless Legs Syndrome, Irritable Bowel Syndrome, physical trauma as a precipitating factor for FMD, anxiety, and poorer physical and mental health. Painkillers were prescribed to 41.6% of patients, yet 39.27% reported pain despite medications, and 39.48% had pain while not receiving analgesics. Conclusions: Pain is highly prevalent in FMD when assessed over the previous 24 h and is frequently reported in patients who are either not receiving analgesics or continue to experience pain despite treatment. Multiple factors influence its intensity and interference in daily life. Longitudinal studies are needed to clarify causal relationships and to inform pain management strategies.

  • Open Access

    Anticholinergic Burden and Botulinum Toxin Needs after Deep Brain Stimulation in Adult and Pediatric Patients with Dystonia

    by Marcela A. Montiel, Alessandro Magliozzi, Wei Kang Lim, Carolina Gorodetsky, George M. Ibrahim, Alfonso Fasano

    Background: Anticholinergic medications and botulinum neurotoxin injections are established treatments for dystonia, yet they carry potential side effects and practical challenges. Deep brain stimulation (DBS) is offered in case of poor response to these approaches. Objectives: To assess the need for anticholinergic medications and botulinum neurotoxin injections in adult and pediatric patients at two specialized Canadian centers before and after DBS over the past 10 years. Methods: 58 patients were included analyzing data before, 6 and 12 months after DBS. Clinical assessment included the Toronto Western Spasmodic Torticollis Rating Scale and Fahn‐Marsden Dystonia Rating Scale. Anticholinergic burden was determined by the Anticholinergic Drug Scale (ADS). Results: Severity of cervical dystonia and ADS scores reduction were statistically significant after DBS. Anticholinergic medication and Botulinum Neurotoxin injections were discontinued a year after surgery in 28.8% and 72.4% of the patients, respectively. Conclusion: Simplification of anti‐dystonia treatments is another added benefit of DBS.


  • Open Access

    Levodopa‐Carbidopa Intestinal Gel in an Outpatient Setting: A 10‐Year Experience

    by Alessandro Magliozzi, Nicholas Feugas, Yu Yan Poon, Taline Naranian, Louis Liu, Yvonne Tse, Anthony E. Lang, Alfonso Fasano